Compare Citius Pharmaceuticals Inc (CTXR) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Marqeta Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Marqeta Inc trades at $15.59 (market cap $1.62B). The key difference: Marqeta Inc is far larger — about 81× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | MQ | |
|---|---|---|
Market Cap | $20.01M | $1.62B |
Sector | Health | Technology |
52-Week High | $1.82 | $26.00 |
52-Week Low | $0.48 | $15.04 |
Enterprise Value | $16.23M | $935.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
MQ trades at $15.59, down slightly by 0.06%. The stock exhibits a bearish technical signal with strong selling pressure on moving averages. Fundamentally, the company shows improving revenue trends, with 2026 revenue projected at $677 million and a return to positive net income. Recent partnerships with Google and Riskified highlight strategic growth initiatives in digital payments and fraud prevention.
MQ's outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but high valuation ratios and past earnings volatility present risks. Analyst consensus is a 'Hold' with a $19 price target, suggesting moderate upside potential from current levels amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
